Baylor College of Medicine

Sang Jun Han

Bert W O'Malley

David Michael Lonard

Prashi Jain

Yosef Gilad

Bryan Nikolai

Clifford Dacso

The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.

Growing community of inventors

Houston, TX, United States of America

Sang Jun Han